Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees
Biosimilars: Considerations for Payers
Projected US Savings From Biosimilars, 2021-2025
Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
Biosimilars (National Psoriasis Foundation)
Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis
Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
